Johnson and Johnson 2015 Annual Report Download - page 25

Download and view the complete annual report

Please find page 25 of the 2015 Johnson and Johnson annual report below. You can navigate through the pages in the report by either clicking on the pages listed below, or by using the keyword search tool below to find specific information within the annual report.

Page out of 112

  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7
  • 8
  • 9
  • 10
  • 11
  • 12
  • 13
  • 14
  • 15
  • 16
  • 17
  • 18
  • 19
  • 20
  • 21
  • 22
  • 23
  • 24
  • 25
  • 26
  • 27
  • 28
  • 29
  • 30
  • 31
  • 32
  • 33
  • 34
  • 35
  • 36
  • 37
  • 38
  • 39
  • 40
  • 41
  • 42
  • 43
  • 44
  • 45
  • 46
  • 47
  • 48
  • 49
  • 50
  • 51
  • 52
  • 53
  • 54
  • 55
  • 56
  • 57
  • 58
  • 59
  • 60
  • 61
  • 62
  • 63
  • 64
  • 65
  • 66
  • 67
  • 68
  • 69
  • 70
  • 71
  • 72
  • 73
  • 74
  • 75
  • 76
  • 77
  • 78
  • 79
  • 80
  • 81
  • 82
  • 83
  • 84
  • 85
  • 86
  • 87
  • 88
  • 89
  • 90
  • 91
  • 92
  • 93
  • 94
  • 95
  • 96
  • 97
  • 98
  • 99
  • 100
  • 101
  • 102
  • 103
  • 104
  • 105
  • 106
  • 107
  • 108
  • 109
  • 110
  • 111
  • 112

Pharmaceutical Segment
Pharmaceutical segment sales in 2015 were $31.4 billion, a decrease of 2.7% from 2014, which included operational
growth of 4.2% offset by a negative currency impact of 6.9%. U.S. sales were $18.3 billion, an increase of 5.2%.
International sales were $13.1 billion, a decrease of 12.0%, which included 3.0% operational growth offset by a negative
currency impact of 15.0%. The Pharmaceutical segment operational growth was negatively impacted by 6.5% due to the
introduction of competitive products to the Company’s Hepatitis C products, OLYSIO®/SOVRIAD®(simeprevir) and
INCIVO®(telaprevir), and positively impacted by 1.4% due to an adjustment to previous reserve estimates, including
Managed Medicaid rebates primarily in the Cardiovascular/Metabolism/Other therapeutic area. In 2015, divestitures had a
negative impact of 0.3% on the worldwide Pharmaceutical segment operational growth.
Major Pharmaceutical Therapeutic Area Sales:*
% Change
(Dollars in Millions) 2015 2014 2013 ’15 vs. ’14 ’14 vs. ’13
Total Immunology $10,402 10,193 9,190 2.1% 10.9
REMICADE®6,561 6,868 6,673 (4.5) 2.9
SIMPONI®/SIMPONI ARIA®1,328 1,187 932 11.9 27.4
STELARA®2,474 2,072 1,504 19.4 37.8
Other Immunology 39 66 81 (40.9) (18.5)
Total Infectious Diseases 3,656 5,599 3,550 (34.7) 57.7
EDURANT®410 365 236 12.3 54.7
OLYSIO®/SOVRIAD®621 2,302 23 (73.0) **
PREZISTA®/ PREZCOBIX®/REZOLSTA®1,810 1,831 1,673 (1.1) 9.4
Other Infectious Diseases 815 1,101 1,618 (26.0) (32.0)
Total Neuroscience 6,259 6,487 6,667 (3.5) (2.7)
CONCERTA®/methylphenidate 821 599 782 37.1 (23.4)
INVEGA®/paliperidone 573 640 583 (10.5) 9.8
INVEGA SUSTENNA®/XEPLION®/INVEGA TRINZA®1,830 1,588 1,248 15.2 27.2
RISPERDAL®CONSTA®970 1,190 1,318 (18.5) (9.7)
Other Neuroscience 2,065 2,470 2,736 (16.4) (9.7)
Total Oncology 4,695 4,457 3,773 5.3 18.1
IMBRUVICA®689 200 — ** —
VELCADE®1,333 1,618 1,660 (17.6) (2.5)
ZYTIGA®2,231 2,237 1,698 (0.3) 31.7
Other Oncology 442 402 415 10.0 (3.1)
Cardiovascular / Metabolism / Other*** 6,418 5,577 4,945 15.1 12.8
XARELTO®1,868 1,522 864 22.7 76.2
INVOKANA®/ INVOKAMET®1,308 586 123 ** **
PROCRIT®/EPREX®1,068 1,238 1,364 (13.7) (9.2)
Other 2,174 2,231 2,594 (2.6) (14.0)
Total Pharmaceutical Sales $31,430 32,313 28,125 (2.7)% 14.9
* Prior year amounts have been reclassified to conform to current year presentation.
** Percentage greater than 100%
*** Previously referred to as Other
Immunology products achieved sales of $10.4 billion in 2015, representing an increase of 2.1% as compared to the prior
year. Immunology products growth of 2.1% included operational growth of 6.9% and a negative currency impact of 4.8%.
The increased sales of STELARA®(ustekinumab) and SIMPONI®/SIMPONI ARIA®(golimumab) were due to market
growth and increased penetration of SIMPONI ARIA®. Growth was partially offset by lower REMICADE®(infliximab) sales
to the Company’s distributor primarily due to the weakening of the euro and biosimilar competition in Europe. The
Johnson & Johnson 2015 Annual Report •13